A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions
There are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and to follow‐up personalized cancer therapy. Fine‐needle aspiration (FNA) biopsy provides ready access to relevant tissues; however, the minute sample amounts r...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-09-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12350 |
id |
doaj-801210110a314b449358aec16284a545 |
---|---|
record_format |
Article |
spelling |
doaj-801210110a314b449358aec16284a5452020-11-25T03:56:53ZengWileyMolecular Oncology1574-78911878-02612018-09-011291415142810.1002/1878-0261.12350A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesionsBo Franzén0Masood Kamali‐Moghaddam1Andrey Alexeyenko2Thomas Hatschek3Susanne Becker4Lotta Wik5Jonas Kierkegaard6Annika Eriksson7Naveen R. Muppani8Gert Auer9Ulf Landegren10Rolf Lewensohn11Department of Oncology and Pathology Cancer Center Karolinska Karolinska Institutet and University Hospital Stockholm SwedenDepartment of Immunology, Genetics and Pathology Science for Life Laboratory Uppsala University SwedenDepartment of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet Stockholm SwedenDepartment of Oncology and Pathology Cancer Center Karolinska Karolinska Institutet and University Hospital Stockholm SwedenDepartment of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet Stockholm SwedenDepartment of Immunology, Genetics and Pathology Science for Life Laboratory Uppsala University SwedenBröstCentrum City Stockholm SwedenKIGene MMK Neurogenetics Unit CMM Karolinska Institutet Stockholm SwedenDepartment of Immunology, Genetics and Pathology Science for Life Laboratory Uppsala University SwedenDepartment of Oncology and Pathology Cancer Center Karolinska Karolinska Institutet and University Hospital Stockholm SwedenDepartment of Immunology, Genetics and Pathology Science for Life Laboratory Uppsala University SwedenDepartment of Oncology and Pathology Cancer Center Karolinska Karolinska Institutet and University Hospital Stockholm SwedenThere are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and to follow‐up personalized cancer therapy. Fine‐needle aspiration (FNA) biopsy provides ready access to relevant tissues; however, the minute sample amounts require sensitive multiplex molecular analysis to achieve clinical utility. We have applied proximity extension assays (PEA) and NanoString (NS) technology for analyses of proteins and of RNA, respectively, in FNA samples. Using samples from patients with breast cancer (BC, n = 25) or benign lesions (n = 33), we demonstrate that these FNA‐based molecular analyses (a) can offer high sensitivity and reproducibility, (b) may provide correct diagnosis in shorter time and at a lower cost than current practice, (c) correlate with results from routine analysis (i.e., benchmarking against immunohistochemistry tests for ER, PR, HER2, and Ki67), and (d) may also help identify new markers related to immunotherapy. A specific 11‐protein signature, including FGF binding protein 1, decorin, and furin, distinguished all cancer patient samples from all benign lesions in our main cohort and in smaller replication cohort. Due to the minimally traumatic sampling and rich molecular information, this combined proteomics and transcriptomic methodology is promising for diagnostics and evaluation of treatment efficacy in BC.https://doi.org/10.1002/1878-0261.12350breast cancer diagnosisfine‐needle aspirationprotein biomarkerproximity extension assay |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bo Franzén Masood Kamali‐Moghaddam Andrey Alexeyenko Thomas Hatschek Susanne Becker Lotta Wik Jonas Kierkegaard Annika Eriksson Naveen R. Muppani Gert Auer Ulf Landegren Rolf Lewensohn |
spellingShingle |
Bo Franzén Masood Kamali‐Moghaddam Andrey Alexeyenko Thomas Hatschek Susanne Becker Lotta Wik Jonas Kierkegaard Annika Eriksson Naveen R. Muppani Gert Auer Ulf Landegren Rolf Lewensohn A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions Molecular Oncology breast cancer diagnosis fine‐needle aspiration protein biomarker proximity extension assay |
author_facet |
Bo Franzén Masood Kamali‐Moghaddam Andrey Alexeyenko Thomas Hatschek Susanne Becker Lotta Wik Jonas Kierkegaard Annika Eriksson Naveen R. Muppani Gert Auer Ulf Landegren Rolf Lewensohn |
author_sort |
Bo Franzén |
title |
A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions |
title_short |
A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions |
title_full |
A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions |
title_fullStr |
A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions |
title_full_unstemmed |
A fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions |
title_sort |
fine‐needle aspiration‐based protein signature discriminates benign from malignant breast lesions |
publisher |
Wiley |
series |
Molecular Oncology |
issn |
1574-7891 1878-0261 |
publishDate |
2018-09-01 |
description |
There are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and to follow‐up personalized cancer therapy. Fine‐needle aspiration (FNA) biopsy provides ready access to relevant tissues; however, the minute sample amounts require sensitive multiplex molecular analysis to achieve clinical utility. We have applied proximity extension assays (PEA) and NanoString (NS) technology for analyses of proteins and of RNA, respectively, in FNA samples. Using samples from patients with breast cancer (BC, n = 25) or benign lesions (n = 33), we demonstrate that these FNA‐based molecular analyses (a) can offer high sensitivity and reproducibility, (b) may provide correct diagnosis in shorter time and at a lower cost than current practice, (c) correlate with results from routine analysis (i.e., benchmarking against immunohistochemistry tests for ER, PR, HER2, and Ki67), and (d) may also help identify new markers related to immunotherapy. A specific 11‐protein signature, including FGF binding protein 1, decorin, and furin, distinguished all cancer patient samples from all benign lesions in our main cohort and in smaller replication cohort. Due to the minimally traumatic sampling and rich molecular information, this combined proteomics and transcriptomic methodology is promising for diagnostics and evaluation of treatment efficacy in BC. |
topic |
breast cancer diagnosis fine‐needle aspiration protein biomarker proximity extension assay |
url |
https://doi.org/10.1002/1878-0261.12350 |
work_keys_str_mv |
AT bofranzen afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT masoodkamalimoghaddam afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT andreyalexeyenko afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT thomashatschek afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT susannebecker afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT lottawik afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT jonaskierkegaard afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT annikaeriksson afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT naveenrmuppani afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT gertauer afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT ulflandegren afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT rolflewensohn afineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT bofranzen fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT masoodkamalimoghaddam fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT andreyalexeyenko fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT thomashatschek fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT susannebecker fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT lottawik fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT jonaskierkegaard fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT annikaeriksson fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT naveenrmuppani fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT gertauer fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT ulflandegren fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions AT rolflewensohn fineneedleaspirationbasedproteinsignaturediscriminatesbenignfrommalignantbreastlesions |
_version_ |
1724463202711896064 |